 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Cyclonamine, Dicynene, Dicynone, Haemostop, Menostat |
| Other names | Diethylammonium 2,5-dihydroxybenzenesulfonate; diethylammonium dobesilate |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.018.265 |
| Chemical and physical data | |
| Formula | C10H17NO5S |
| Molar mass | 263.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Etamsylate (sometimes spelledethamsylate) is anantihemorrhagic agent which is believed to work by increasing resistance in theendothelium ofcapillaries and promotingplatelet adhesion.[1][2] It also inhibitsbiosynthesis and action of thoseprostaglandins which cause platelet disaggregation,vasodilation and increased capillary permeability.[3]
Etamsylate is thesalt ofdobesilic acid anddiethylamine.
Prophylaxis and control of haemorrhages from small blood vessels, neonatal intraventricular haemorrhage,[4]: 1065 capillary bleeding of different etiology, including: menorrhagia and metrorrhagia without organic pathology, after trans-urethral resection of the prostate, hematemesis, melena, hematuria, epistaxis; secondary bleeding due to thrombocytopenia or thrombocytopathia, hypocoagulation, prevention of periventricular hemorrhages in prematurely born children.[5]
Etamsylate is a haemostatic agent; also promotesangioprotective and proaggregant action. It stimulatesthrombopoiesis and their release from bone marrow. Haemostatic action is due to activation of thromboplastin formation on damaged sites of small blood vessels and decrease of PgI2 (Prostacyclin) synthesis; it also facilitates platelet aggregation andadhesion, that at last induce decrease and stop of hemorrhage.[6]
The precisemechanism of action of etamsylate is unknown. It has been shown to reduce bleeding time and blood loss from wounds. This appears to relate to increased platelet aggregation mediated by a thromboxane A2 or prostaglandin F2a dependent mechanism. It has also been associated with decreased concentrations of 6-oxoprostaglandin F1a, a stable metabolite of prostacyclin. Prostacyclin is a potent vasodilator, and may be implicated in reperfusion; it is also a disaggregator of platelets. Whereas prostaglandins themselves may have a role in regulating cerebral blood flow, etamsylate appears to have no effect on cerebral blood flow. Etamsylate was also thought to stabilize capillaries, reinforcing capillary membranes by polymerizinghyaluronic acid.[7]
Etamsylate limits capillary bleeding through its action on hyaluronic acid and initial studies showed a reduction in intraventricular haemorrhage.[4]: 1050
Etamsylate may also have an effect on the microcirculation, encouraging platelet aggregation and vasoconstriction and therefore haemostasis. It also inhibits the effects of the prostaglandin mediated vasodilatation and increased capillary permeability, thereby reducing oedema secondary to capillary leakage. It is also possible that etamsylate would reduce reperfusion haemorrhage in ischaemic areas of the brain, preventing secondary damage.[1]
By inhibiting the effects of prostaglandins, etamsylate may exert an effect by closing the patent ductus and thereby increasing cerebral blood flow.[8] Further, etamsylate has demonstrated interference with heparin, antagonizing its pro-hemorrhagic and anti-coagulant effects, without inhibiting its vasodilatory properties.[9]
In July 2025, theCommittee for Veterinary Medicinal Products of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Hemosyvet, solution for injection, intended for cats, cattle, dogs, goats, horses, pigs, and sheep.[10] The applicant for this veterinary medicinal product is Axience.[10] Hemosyvet is an hemostatic and angio-protective medicinal product containing etamsylate as the active substance which stimulates platelet adhesiveness, shortening bleeding time, and rapidly and lastingly normalizes the altered vascular fragility and permeability.[10]
